Long-term efficacy and safety of fourth-line multikinase inhibitor treatment with lenvatinib in a young papillary thyroid carcinoma patient
Lenvatinib, a multikinase inhibitor, is approved for the treatment of patients with radioiodine-refractory metastatic thyroid cancer on the basis of a Phase III, prospective, double-blind, randomized, placebo-controlled trial that showed longer progression-free survival in the drug-treated arm. Here...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BioExcel Publishing Ltd
2017-07-01
|
| Series: | Drugs in Context |
| Subjects: | |
| Online Access: | http://www.drugsincontext.com/long-term-efficacy-safety-fourth-line-multikinase-inhibitor-treatment-lenvatinib-young-papillary-thyroid-carcinoma-patient/ |